
Suzanne L Topalian

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2788264/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer. New England Journal of Medicine, 2012, 366, 2443-2454.	27.0	10,727
2	Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer. New England Journal of Medicine, 2012, 366, 2455-2465.	27.0	6,820
3	Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy. Cancer Cell, 2015, 27, 450-461.	16.8	3,266
4	Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates. Journal of Clinical Oncology, 2010, 28, 3167-3175.	1.6	2,667
5	Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes. Science, 2006, 314, 126-129.	12.6	2,352
6	Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nature Reviews Cancer, 2016, 16, 275-287.	28.4	2,133
7	Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti–PD-1 Therapy. Clinical Cancer Research, 2014, 20, 5064-5074.	7.0	2,050
8	Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab. Journal of Clinical Oncology, 2014, 32, 1020-1030.	1.6	2,015
9	Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape. Science Translational Medicine, 2012, 4, 127ra37.	12.4	1,837
10	Neoadjuvant PD-1 Blockade in Resectable Lung Cancer. New England Journal of Medicine, 2018, 378, 1976-1986.	27.0	1,495
11	Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 8372-8377.	7.1	1,482
12	Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Current Opinion in Immunology, 2012, 24, 207-212.	5.5	1,186
13	PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma. New England Journal of Medicine, 2016, 374, 2542-2552.	27.0	1,048
14	Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558,) Tj ET Clinical Oncology, 2015, 33, 2004-2012.	۲Qq0 0 0 r 1.6	gBT /Overlocl 1,035
15	Autoimmunity Correlates With Tumor Regression in Patients With Metastatic Melanoma Treated With Anti–Cytotoxic T-Lymphocyte Antigen-4. Journal of Clinical Oncology, 2005, 23, 6043-6053.	1.6	989
16	Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma. Journal of Clinical Oncology, 2017, 35, 785-792.	1.6	930
17	Enterocolitis in Patients With Cancer After Antibody Blockade of Cytotoxic T-Lymphocyte–Associated Antigen 4. Journal of Clinical Oncology, 2006, 24, 2283-2289.	1.6	794
18	Evidence for a Role of the PD-1:PD-L1 Pathway in Immune Resistance of HPV-Associated Head and Neck Squamous Cell Carcinoma. Cancer Research, 2013, 73, 1733-1741.	0.9	678

SUZANNE L TOPALIAN

#	Article	IF	CITATIONS
19	lpilimumab (Anti-CTLA4 Antibody) Causes Regression of Metastatic Renal Cell Cancer Associated With Enteritis and Hypophysitis. Journal of Immunotherapy, 2007, 30, 825-830.	2.4	656
20	The role of CD4+ T cell responses in antitumor immunity. Current Opinion in Immunology, 1998, 10, 588-594.	5.5	593
21	Neoadjuvant checkpoint blockade for cancer immunotherapy. Science, 2020, 367, .	12.6	553
22	Durable Cancer Regression Off-Treatment and Effective Reinduction Therapy with an Anti-PD-1 Antibody. Clinical Cancer Research, 2013, 19, 462-468.	7.0	485
23	Cancer Immunotherapy Comes of Age. Journal of Clinical Oncology, 2011, 29, 4828-4836.	1.6	411
24	Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non–Small Cell Lung Cancer Treated With Nivolumab. JAMA Oncology, 2019, 5, 1411.	7.1	388
25	Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab. Journal of Clinical Oncology, 2015, 33, 2013-2020.	1.6	385
26	Alterations of immune response of non-small cell lung cancer with Azacytidine. Oncotarget, 2013, 4, 2067-2079.	1.8	336
27	PD-L1 Expression in the Merkel Cell Carcinoma Microenvironment: Association with Inflammation, Merkel Cell Polyomavirus, and Overall Survival. Cancer Immunology Research, 2013, 1, 54-63.	3.4	333
28	A Phase I Study of Nonmyeloablative Chemotherapy and Adoptive Transfer of Autologous Tumor Antigen-Specific T Lymphocytes in Patients With Metastatic Melanoma. Journal of Immunotherapy, 2002, 25, 243-251.	2.4	326
29	Cytotoxic T-Lymphocyte-Associated Antigen-4 Blockage Can Induce Autoimmune Hypophysitis in Patients With Metastatic Melanoma and Renal Cancer. Journal of Immunotherapy, 2005, 28, 593-598.	2.4	315
30	Mechanisms regulating PD-L1 expression on tumor and immune cells. , 2019, 7, 305.		291
31	Antagonists of PD-1 and PD-L1 in Cancer Treatment. Seminars in Oncology, 2015, 42, 587-600.	2.2	259
32	Intrapatient Dose Escalation of Anti–CTLA-4 Antibody in Patients With Metastatic Melanoma. Journal of Immunotherapy, 2006, 29, 455-463.	2.4	246
33	Differential Expression of Immune-Regulatory Genes Associated with PD-L1 Display in Melanoma: Implications for PD-1 Pathway Blockade. Clinical Cancer Research, 2015, 21, 3969-3976.	7.0	205
34	Conserved Interferon-Î ³ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma. Cancer Cell, 2020, 38, 500-515.e3.	16.8	203
35	Neoadjuvant Nivolumab for Patients With Resectable Merkel Cell Carcinoma in the CheckMate 358 Trial. Journal of Clinical Oncology, 2020, 38, 2476-2487.	1.6	152
36	A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma. Journal of Immunotherapy, 2002, 25, 243-51.	2.4	139

SUZANNE L TOPALIAN

#	Article	IF	CITATIONS
37	The Intratumoral Balance between Metabolic and Immunologic Gene Expression Is Associated with Anti–PD-1 Response in Patients with Renal Cell Carcinoma. Cancer Immunology Research, 2016, 4, 726-733.	3.4	133
38	Multidimensional, quantitative assessment of PD-1/PD-L1 expression in patients with Merkel cell carcinoma and association with response to pembrolizumab. , 2018, 6, 99.		129
39	Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce. , 2020, 8, e000398.		125
40	Analysis of multispectral imaging with the AstroPath platform informs efficacy of PD-1 blockade. Science, 2021, 372, .	12.6	114
41	Targeting Immune Checkpoints in Cancer Therapy. JAMA - Journal of the American Medical Association, 2017, 318, 1647.	7.4	111
42	Opportunities and Challenges in the Development of Experimental Drug Combinations for Cancer. Journal of the National Cancer Institute, 2011, 103, 1222-1226.	6.3	100
43	Pan-Tumor Pathologic Scoring of Response to PD-(L)1 Blockade. Clinical Cancer Research, 2020, 26, 545-551.	7.0	100
44	Identification of tumor-associated, MHC class II-restricted phosphopeptides as targets for immunotherapy. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 12073-12078.	7.1	98
45	Structural basis for the recognition of mutant self by a tumor-specific, MHC class II–restricted T cell receptor. Nature Immunology, 2007, 8, 398-408.	14.5	91
46	Neoadjuvant nivolumab for patients with resectable HPV-positive and HPV-negative squamous cell carcinomas of the head and neck in the CheckMate 358 trial. , 2021, 9, e002568.		87
47	Safety and immunologic correlates of Melanoma GVAX, a GM-CSF secreting allogeneic melanoma cell vaccine administered in the adjuvant setting. Journal of Translational Medicine, 2015, 13, 214.	4.4	84
48	Transcriptional Mechanisms of Resistance to Anti–PD-1 Therapy. Clinical Cancer Research, 2017, 23, 3168-3180.	7.0	67
49	Association of HIV Status With Local Immune Response to Anal Squamous Cell Carcinoma. JAMA Oncology, 2017, 3, 974.	7.1	65
50	Evaluation of Prime/Boost Regimens Using Recombinant Poxvirus/Tyrosinase Vaccines for the Treatment of Patients with Metastatic Melanoma. Clinical Cancer Research, 2006, 12, 2526-2537.	7.0	50
51	PD-L1 Expression in Melanocytic Lesions Does Not Correlate with the BRAF V600E Mutation. Cancer Immunology Research, 2015, 3, 110-115.	3.4	45
52	Integrative Tumor and Immune Cell Multi-omic Analyses Predict Response to Immune Checkpoint Blockade in Melanoma. Cell Reports Medicine, 2020, 1, 100139.	6.5	45
53	Structural insights into the editing of germ-line-encoded interactions between T-cell receptor and MHC class II by VÂ CDR3. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 14960-14965.	7.1	39
54	Structural Basis for the Presentation of Tumor-Associated MHC Class II-Restricted Phosphopeptides to CD4+ T Cells. Journal of Molecular Biology, 2010, 399, 596-603.	4.2	37

SUZANNE L TOPALIAN

#	Article	IF	CITATIONS
55	Th17 immune microenvironment in Epstein-Barr virus–negative Hodgkin lymphoma: implications for immunotherapy. Blood Advances, 2017, 1, 1324-1334.	5.2	36
56	Merkel cell polyomavirus-specific immune responses in patients with Merkel cell carcinoma receiving anti-PD-1 therapy. , 2018, 6, 131.		35
57	Identification and Characterization of Complex Glycosylated Peptides Presented by the MHC Class II Processing Pathway in Melanoma. Journal of Proteome Research, 2017, 16, 228-237.	3.7	34
58	Balance and Imbalance in the Immune System: Life on the Edge. Immunity, 2014, 41, 682-684.	14.3	33
59	Structure-Based Design of Altered MHC Class II–Restricted Peptide Ligands with Heterogeneous Immunogenicity. Journal of Immunology, 2013, 191, 5097-5106.	0.8	18
60	The Genetic Evolution of Treatment-Resistant Cutaneous, Acral, and Uveal Melanomas. Clinical Cancer Research, 2021, 27, 1516-1525.	7.0	6
61	Neoadjuvant Therapy for Melanoma: A U.S. Food and Drug Administration—Melanoma Research Alliance Public Workshop. Clinical Cancer Research, 2021, 27, 394-401.	7.0	5
62	Society for immunotherapy of cancer (SITC) statement on the proposed changes to the common rule. , 2016, 4, 37.		1
63	Tumorâ€associated MHC IIâ€restricted phosphopeptides: New targets for immune recognition. FASEB Journal, 2008, 22, 1079.1.	0.5	1